Transcatheter Mitral Valve Replacement for Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Using Balloon-Expandable Transcatheter Heart Valves

Alessandro Sticchi, David Reineke, Fabien Praz, Stephan Windecker, Alessandro Sticchi, David Reineke, Fabien Praz, Stephan Windecker

No abstract available

Keywords: TMVR; mitral valve; valve-in-MAC (ViMAC); valve-in-ring (ViR); valve-in-valve (ViV).

Conflict of interest statement

Funding Support and Author Disclosures Dr. Windecker has received research and educational grants to the institution from Abbott, Amgen, Bristol Myers Squibb, Bayer, Boston Scientific, Biotronik, Cardinal Health, Cardiovalve, CSL Behring, Daiichi-Sankyo, Edwards Lifesciences, Johnson & Johnson, Medtronic, Querbet, Polares, Sanofi, Terumo, and Sinomed; serves as an unpaid advisory board member and/or unpaid member of the steering or executive committees of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bristol Myers Squibb, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis but has not received personal payments from pharmaceutical companies or device manufacturers; is a member of the steering or executive committees of several investigated-initiated trials that receive funding from industry, without impact on his personal remuneration; and is an unpaid member of the Pfizer Research Award selection committee in Switzerland. Dr. Praz has received travel expenses from Abbott Vascular, Edwards Lifesciences, and Polares Medical. Dr. Reineke has a consultancy agreement with Abbott; has received proctoring fees from Abbott; and has received travel expenses from Abbott. Dr. Sticchi has reported that he has no relationships relevant to the contents of this paper to disclose.